NCT02328144

Brief Summary

Hemorrhoidal disease occurs in 50% of people over 40 years old and is the most common cause of anorectal surgery. One of the complications of hemorrhoidectomy is pain, which is a difficult symptom to appreciate and assess, by its frequent and large variations in sensitivity in each patient. Many studies have been done to reduce patient postoperative pain, but there is no ideal method. The application of both oral and topical metronidazole has shown to decrease pain following hemorrhoidectomy, but its use is not standardized. The investigators evaluated the effect of oral administration of metronidazole versus homologated placebo in pain control after hemorrhoidectomy

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
44

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Jul 2013

Shorter than P25 for phase_3

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2013

Completed
1.1 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 1, 2014

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2014

Completed
3 months until next milestone

First Submitted

Initial submission to the registry

December 22, 2014

Completed
9 days until next milestone

First Posted

Study publicly available on registry

December 31, 2014

Completed
Last Updated

December 31, 2014

Status Verified

December 1, 2014

Enrollment Period

1.1 years

First QC Date

December 22, 2014

Last Update Submit

December 26, 2014

Conditions

Keywords

HemorrhoidectomyPostoperative painMetronidazole

Outcome Measures

Primary Outcomes (1)

  • Pain evolution, hours and days after surgery

    Pain was assessed with the visual analogue scale questionnaire

    6 and 12 hours, 1, 4, 7 and 14 days

Secondary Outcomes (5)

  • Interleukin

    after surgery and 12 hours

  • Analgesics

    6 and 12 hours, 1, 4, 7 and 14 days

  • Surgery complications

    6 and 12 hours, 1, 4, 7 and 14 days

  • Return to normal activities

    1, 4, 7 and 14 days

  • Satisfaction

    14 day

Study Arms (2)

Metronidazole

ACTIVE COMPARATOR

22 patients received oral metronidazole 500mg 3 times for day for 7 days

Drug: Metronidazole

Placebo

PLACEBO COMPARATOR

22 patients received oral placebo 500mg 3 times for day for 7 days

Drug: Placebo

Interventions

Patients were assigned to two groups, one of them received oral metronidazole (study group) and the other, homologated placebo (control group) after hemorrhoidectomy. Then, postoperative pain was assessed by visual analog scale at 6 and 12hrs, 1, 4, 7 and 14 days

Also known as: Flagyl
Metronidazole

Patients were assigned to two groups, one of them received oral metronidazole (study group) and the other, homologated placebo (control group) after hemorrhoidectomy. Then, postoperative pain was assessed by visual analog scale at 6 and 12hrs, 1, 4, 7 and 14 days.

Also known as: Homologated Placebo
Placebo

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Hemorrhoidal disease grade III and IV
  • Informed consent

You may not qualify if:

  • Pregnancy
  • Lactation
  • Other anorectal disease
  • Previous anorectal
  • hypersensibility to metronidazole

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Western Medical Center, Mexican Institute of Social Security

Guadalajara, Jalisco, 44340, Mexico

Location

MeSH Terms

Conditions

HemorrhoidsPain, Postoperative

Interventions

Metronidazole

Condition Hierarchy (Ancestors)

Rectal DiseasesIntestinal DiseasesGastrointestinal DiseasesDigestive System DiseasesVascular DiseasesCardiovascular DiseasesPostoperative ComplicationsPathologic ProcessesPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsSigns and Symptoms

Intervention Hierarchy (Ancestors)

NitroimidazolesNitro CompoundsOrganic ChemicalsImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic Compounds

Study Officials

  • Clotilde Fuentes-Orozco, PhD

    Instituto Mexicano del Seguro Social

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
DOUBLE
Who Masked
PARTICIPANT, INVESTIGATOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
PhD

Study Record Dates

First Submitted

December 22, 2014

First Posted

December 31, 2014

Study Start

July 1, 2013

Primary Completion

August 1, 2014

Study Completion

October 1, 2014

Last Updated

December 31, 2014

Record last verified: 2014-12

Locations